SYNGENE Q2 FY26 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹911 Cr
verified against source
Revenue YoY
2%
reported change
EBITDA
₹200 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Syngene reported a muted Q2 FY26 with revenue of INR 911 crore (up 2% YoY) as robust research services growth was offset by anticipated inventory correction in biologics manufacturing. EBITDA declined 18% to INR 200 crore with margins compressing 500bps to 22%, while PAT fell 37% to INR 67 crore due to higher depreciation from newly operational facilities. H1 performance was in line with guidance. The company secured its first global Phase III clinical trial with a U.S. biotech, marking a strategic milestone in clinical research. Management maintained full-year guidance of mid-single-digit revenue growth and mid-20s EBITDA margins, characterizing FY2026 as a transient year driven by inventory destocking and new facility ramp-up costs. Key growth vectors include ADC bioconjugation capabilities, peptide manufacturing scale-up in Mangaluru, and the Bayview (U.S.) facility expected to commence operations in H2. Risk includes prolonged biologics inventory correction beyond guidance period and slower-than-expected ramp of newly commissioned facilities.
Colored figures show movement against the previous available record.
Guidance to track
- Management maintained guidance for mid-single-digit revenue growth on both reported and constant currency basis, driven by research services momentum and recovery in biologics H2.
- Full-year EBITDA margins expected in mid-20s (vs 22% in Q2) as H2 typically stronger than H1; transient year due to new facility ramp-up costs.
- PAT expected to decline year-on-year due to higher depreciation from Bangalore Unit 3 and Bayview facility preparations alongside lower margins.
- U.S. biologics manufacturing facility in Baltimore remains on track to commence operations in second half of FY2026, with monetization beginning after trial batches.
Risks flagged
- The Zoetis animal health biologic restocking was expected to normalize through FY2026, but management declined to confirm whether normal ordering patterns resume in FY2027, suggesting potential for extended headwinds beyond initial guidance period.
- Management repeatedly refused to provide margin or revenue comparison data for the Phase III clinical trial business vs traditional research/CDMO services, citing competitive reasons. The scalability and profitability of this new strategic direction remains unquantified.
- INR 28 crore write-off of unrecoverable receivables recorded in other expenses — a one-off charge that may indicate customer credit quality concerns or contract disputes not explicitly addressed.
- Analyst Aditya Cheda raised concerns about ROE profile deteriorating from both lower asset turns (new facilities) and lower margins. Management acknowledged muted returns but provided only a 3-5 year horizon for asset turnover improvement without committing to specific ROE targets.
Key quotes
- FY 2026 being a transient year. On a reported basis and in constant currency, we guided to a mid-single-digit growth on revenue. We also guided towards a mid-20s EBITDA margin and a declining PAT. We continue to hold our guidance for the full year.
- This trial will recruit patients across clinical sites both in India and the United States. This is an important milestone and reflects our growing capabilities in managing large, complex global trials. The economics of this trial will be spread out over three years, and the bulk of that will come in FY 2027 and 2028 as the trial recruits pick up.
- We saw the impact of restocking happening in quarter two. That was in line with our anticipation or our expectations as well. We are working with the client to ensure that it is going as what we had anticipated it to be.
Research modules